PFE
Pfizer Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Pfizer has 14 disclosed suppliers and 21 disclosed customers in SEC filings.
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+1.52%
vs ±3.3% implied · ×0.46
shaded = implied · ▲▼ = realized
SentenceRevenue from UCB, Baxalta, AstraZeneca, Pfizer Inc., and Roche represented 39 %, 18 %, 17 %, 12 % and 10 % of our revenue, respectively, for the year ended December 31, 2024.
basisNKTR FY2025 revenue $55MPFE FY2025 revenue $62.6B
SentenceIn December 2025, we entered into two non-exclusive agreements with Pfizer Inc. ("Pfizer") to leverage proprietary TCR discovery platform and its large‑scale immune receptor–antigen mapping datasets to accelerate therapeutic research in rheumatoid arthritis ("RA") and broader immunology applications.
SentenceIn July 2021, we entered into the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer, pursuant to which we granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing our proprietary compound vepdegestrant (ARV-471), or the Licensed Products.
SentenceIn December 2021, we entered into a four-year research collaboration agreement, or the Pfizer Agreement, with Pfizer Inc., or Pfizer, focused on in vivo base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system.
SentenceThis increase was partially offset by the non-recurrence of $6.0 million revenue from our licensing agreement with Roche Sequencing Solutions, Inc. ("Roche") entered into in February 2024, and $9.5 million of revenue related to a license agreement with Pfizer Inc. ("Pfizer") entered into in December 2024.
SentenceFor example, in April 2020 we entered into a research collaboration and license agreement with Pfizer in connection with VLA15, our Lyme disease vaccine candidate. Pursuant to this agreement, Pfizer is leading late-stage development of the vaccine candidate, including conducting the ongoing Phase 3 clinical trials, and, if the Phase 3 data are positive, will have sole control over the timing and nature of its commercialization, which will have a significant impact on Valneva
SentenceIn April 2018, we acquired certain assets from Pfizer Inc. (Pfizer), including strategic license and collaboration agreements and other intellectual property related to the development and administration of allogeneic CAR T cells for the treatment of cancer.
SentenceIn January 2020, the Company entered into an exclusive license agreement with Pfizer Inc. ("Pfizer") for Pfizer's clinical and non-clinical data, and intellectual property for reboxetine, the active pharmaceutical ingredient in AXS-12 which the Company is developing for the treatment of narcolepsy.
SentenceThrough the Shire License Agreement, we were assigned the rights to the license agreement ("Pfizer Agreement"), with Pfizer Inc. ("Pfizer"), pursuant to which we obtained an exclusive, worldwide license to Pfizer's know-how related to Livmarli, (the "Pfizer Know-How").
SentenceUnder the Pfizer Agreement, Pfizer was obligated to transfer to us certain information, records, regulatory filings, materials and inventory controlled by Pfizer and relating to or useful for developing these compounds and to continue to conduct certain ongoing clinical studies until a certain time.
SentenceIn December 2020, the Company entered into a license agreement (as amended, the "Pfizer License Agreement") with Pfizer Inc. ("Pfizer") for worldwide development and commercialization rights to ADC product candidates directed to certain licensed targets, including MICVO and PYX-203, and products containing the ADC product candidates.
Pfizer Inc
30.46
Expected move
Inputs8Q avg ±2.2%·×1.21·rich
straddle ±3.7%
spot 30.52exp Nov 6ATM strike 30.5ATM straddle 1.34IV 40%